# Dose Escalation and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis

> **NCT01730716** · PHASE2 · UNKNOWN · sponsor: **Neuralstem Inc.** · enrollment: 18 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DEVICE:** Human spinal cord stem cell implantation

## Key facts

- **NCT ID:** NCT01730716
- **Lead sponsor:** Neuralstem Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-05
- **Primary completion:** 2015-12
- **Final completion:** 2016-11
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2015-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01730716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01730716, "Dose Escalation and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01730716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*